https://www.nature.com/articles/d41586-024-03129-3 Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 26 September 2024 Stem cells reverse woman's diabetes -- a world first She is the first person with type 1 diabetes to receive this kind of transplant. By * Smriti Mallapaty 1. Smriti Mallapaty View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email Coloured scanning electron micrograph (SEM) of a cell in an islet of Langerhans from the pancreas. A woman with type 1 diabetes started producing insulin (blue) after a stem cell transplant.Credit: Lennart Nilsson, Boehringer Ingelheim International GmbH, TT/Science Photo Library A 25-year-old woman with type 1 diabetes started producing her own insulin less than three months after receiving a transplant of reprogrammed stem cells^1. She is the first person with the disease to be treated using cells that were extracted from her own body. "I can eat sugar now," said the woman, who lives in Tianjing, on a call with Nature. It has been more than a year since the transplant, and, she says, "I enjoy eating everything -- especially hotpot." The woman asked to remain anonymous to protect her privacy. James Shapiro, a transplant surgeon and researcher at the University of Alberta in Edmonton, Canada, says the results of the surgery are stunning. "They've completely reversed diabetes in the patient, who was requiring substantial amounts of insulin beforehand." The study, published in Cell today, follows results from a separate group in Shanghai, China, who reported in April that they had successfully transplanted insulin-producing islets into the liver of a 59-year-old man with type 2 diabetes^2. The islets were also derived from reprogrammed stem cells taken from the man's own body and he has since stopped taking insulin. The studies are among a handful of pioneering trials using stem cells to treat diabetes, which affects close to half a billion people worldwide. Most of them have type 2 diabetes, in which the body doesn't produce enough insulin or its ability to use the hormone diminishes. In type 1 diabetes, the immune system attacks islet cells in the pancreas. Islet transplants can treat the disease, but there aren't enough donors to meet the growing demand, and recipients must use immune-suppressing drugs to prevent the body from rejecting the donor tissue. Stem cells can be used to grow any tissue in the body and can be cultured indefinitely in the laboratory, which means they potentially offer a limitless source of pancreatic tissue. By using tissue made from a person's own cells, researchers also hope to avoid the need for immunosuppressants. Reprogrammed cells In the first trial of its kind, Deng Hongkui, a cell biologist at Peking University in Beijing, and his colleagues extracted cells from three people with type 1 diabetes and reverted them into a pluripotent state, from which they could be moulded into any cell type in the body. This reprogramming technique was first developed by Shinya Yamanaka at Kyoto University in Japan almost two decades ago. But Deng and his colleagues modified the technique^3: instead of introducing proteins that trigger gene expression, as Yamanaka had done, they exposed the cells to small molecules. This offered more control over the process. The researchers then used the chemically induced pluripotent stem (iPS) cells to generate 3D clusters of islets. They tested the safety and efficacy of the cells in mice and non-human primates. In June 2023, in an operation that lasted less than half an hour, they injected the equivalent of roughly 1.5 million islets into the woman's abdominal muscles -- a new site for islet transplants. Most islet transplants are injected into the liver, where the cells cannot be observed. But by placing them in the abdomen, the researchers could monitor the cells using magnetic resonance imaging, and potentially remove them if needed. Insulin free Two-and-a-half months later, the woman was producing enough insulin to live without needing top-ups, and she has sustained that level of production for more than a year. By that time, the woman had stopped experiencing the dangerous spikes and drops in blood glucose levels, which remained within a target range for more than 98% of the day. "That's remarkable," says Daisuke Yabe, a diabetes researcher at Kyoto University. "If this is applicable to other patients, it's going to be wonderful." The results are intriguing, but they need to be replicated in more people, says Jay Skyler, an endocrinologist at the University of Miami, Florida, who studies type 1 diabetes. Skyler also wants to see that the woman's cells continue to produce insulin for up to five years, before considering her 'cured'. Deng says the results for the other two participants are "also very positive", and they will reach the one-year mark in November, after which he hopes to expand the trial to another 10 or 20 individuals. Because the woman was already receiving immunosuppressants for a previous liver transplant, the researchers could not assess whether the iPS cells reduced the risk of rejection of the graft. Even if the body doesn't reject the transplant because it doesn't consider the cells to be 'foreign', in people with type 1 diabetes, because they have an autoimmune condition, there is still a risk that the body could attack the islets. Deng says they didn't see this in the woman because of the immunosuppressants, but they are trying to develop cells that can evade this autoimmune response. Donor cells Transplants using the recipient's own cells have advantages, but the procedures are difficult to scale up and commercialize, say researchers. Several groups have started trials of islet cells created using donor stem cells. Preliminary results for one trial, led by Vertex Pharmaceuticals in Boston, Massachusetts, were reported in June. A dozen participants with type 1 diabetes received islets derived from donated embryonic stem cells that were injected into the liver. They were all treated with immunosuppressants. Three months after the transplant, all the participants began producing insulin when glucose was present in their bloodstreams^4. Some had become insulin independent. Last year, Vertex launched another trial in which islet cells derived from donated stem cells were placed in a device designed to protect them from immune-system attacks. It was transplanted into a person with type 1 diabetes, who did not receive immunosuppressants. "That trial is ongoing," says Shapiro, who is involved in the study, which aims to enrol 17 individuals. Yabe is also about to start a trial using islet cells produced using donor iPS cells. He plans to develop sheets of islets and surgically place them in the abdominal tissue of three people with type 1 diabetes, who will receive immunosuppressants. The first participant should receive their transplant early next year. doi: https://doi.org/10.1038/d41586-024-03129-3 References 1. Wang, S. et al. Cell 187, 1-13 (2024). Article Google Scholar 2. Wu, J. et al. Cell Discov. 10, 45 (2024). Article PubMed Google Scholar 3. Guan, J. et al. Nature 605, 325-331 (2022). Article PubMed Google Scholar 4. Reichman, T. W. et al. Diabetes 72, 836-P (2023). Article Google Scholar Download references Reprints and permissions Subjects * Stem cells * Diabetes * Cell biology Latest on: Stem cells Single-cell multi-omics map of human fetal blood in Down syndrome Single-cell multi-omics map of human fetal blood in Down syndrome Article 25 SEP 24 Temporal BMP4 effects on mouse embryonic and extraembryonic development Temporal BMP4 effects on mouse embryonic and extraembryonic development Article 18 SEP 24 Gasdermin D-mediated metabolic crosstalk promotes tissue repair Article 11 SEP 24 Diabetes Brain goop that traps hunger neurons drives obesity Brain goop that traps hunger neurons drives obesity News 18 SEP 24 40 million deaths by 2050: toll of drug-resistant infections to rise by 70% 40 million deaths by 2050: toll of drug-resistant infections to rise by 70% News 17 SEP 24 How rival weight-loss drugs fare at treating obesity, diabetes and more How rival weight-loss drugs fare at treating obesity, diabetes and more News 03 SEP 24 Cell biology AARS1 and AARS2 sense l-lactate to regulate cGAS as global lysine lactyltransferases AARS1 and AARS2 sense l-lactate to regulate cGAS as global lysine lactyltransferases Article 25 SEP 24 What is a cell type, really? The quest to categorize life's myriad forms What is a cell type, really? The quest to categorize life's myriad forms News Feature 24 SEP 24 The human heart shows signs of ageing after just a month in space The human heart shows signs of ageing after just a month in space News 24 SEP 24 Nature Careers Jobs * Locum Chief Editor, Nature Structural & Molecular Biology Job Title: Locum Chief Editor, Nature Structural & Molecular Biology Location: New York or Milan Closing date: Friday, October 18th This job is of... New York City, New York (US) Springer Nature Ltd [] * Postdoc Fellow in Cardiology Looking for postdoctoral fellow to study immunometabolic derangements associated with heart failure sterile inflammation. University of Washington, Seattle University of Washington - Cardiology [] * Faculty(Group Leaders or Principal Investigators) and Postdoc positions Faculty and Postdoc positions are open all year. Hangzhou, Zhejiang, China The Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine(ZJUSS) [] * Tenure-track Assistant Professor in Modelling Plant Stress Responses Become a tenure-track Assistant Professor focusing on modelling plant stress responses at Umea Plant Science Centre and IceLab, Umea University! Umea (Stad), Vasterbotten (SE) Umea University (KBC) [] * Faculty Positions in Westlake University Founded in 2018, Westlake University is a new type of non-profit research-oriented university in Hangzhou, China, supported by public a... Hangzhou, Zhejiang, China Westlake University [] You have full access to this article via your institution. Download PDF Subjects * Stem cells * Diabetes * Cell biology Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * protocols.io * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Professional development * Nature Careers * Nature Conferences Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Middle East * Privacy Policy * Use of cookies * Your privacy choices/Manage cookies * Legal notice * Accessibility statement * Terms & Conditions * Your US state privacy rights Springer Nature (c) 2024 Springer Nature Limited